Page 3 - Scientific Library

Whether you wish to perform protein expression profiling for biomarker validation, are deciphering a disease physio-pathology, are looking for the right target to study the effect of your compounds or

One of the challenges in R&D is to find robust technologies to develop diagnostic tests. Notably, it could be within a context of asymptomatic infections for which reliable detection of positive specimens

A new Hemoglobin (Hgb) High Sensitivity kit has just been released to allow for the detection of Hgb in low amount of samples. Researchers working on inflammation, kidney injury or oxidative

As they say, a good picture is worth a thousand words. That's to say that I'll have to keep the introduction short in this post (!) to let you know about this interesting map from Boster Bio

If your research interest is focused on the identification of cell signalling pathways and protein phosphorylation profiles, the comprehensive Phospho Explorer Array may be of great help

RayBiotech , the antibody array specialist, have just released a new, very broad antibody microarray, the L2000 series, for the profiling of 2000 protein targets including

In a previous post, I introduced the G-Series Mouse antibody arrays to profile up to 200 mouse proteins using a combination of 5 antibody arrays on glass slide. This new Mouse L2 L-Series

In a previous post, I introduced Sekisui Xenotech's Research Biobank, which is based on rejections from liver transplantation as opposed to post-mortem tissues, thus offering a guarantee

High density antibody arrays represent powerful technologies which have opened a new era in functional proteomics. However, when faced with a large magnitude of array data, you must apply comprehensive

I just want to briefly outline in this post the power of antibody microarray when it comes to time and cost saving as well as versatility. Whether you want to do multiple profiling or

Tropical and vector-borne diseases account for more than 17% of all infectious diseases, causing more than 1 million deaths annually. Recognizing infected patients early in their clinical course is critical

In new drug development pipelines, there is an increasing trend to switch from "small" to "large" molecules (also known as biologics). While the FDA guidance was quite specific with their recommendations